Browsing by Author "Ilarionova M."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Antileukemic activity of epirubicin conjugated with biopolymer dextran against lymphoid leukemia l1210 as tumor model
    (2004-01-01) Todorova N.; Ilarionova M.; Todorov K.; Todorov D.
    The antileukemic activity of the original conjugate of anthracycline antitumor antibiotic epirubicin, covalently bound to the biopolymer dextran was studied. The ascitic lymphoid leukemia L 1210 (transplantation dose 1x105 tumor cells/mouse, i. p.), in hybrid mice BDF1, was used as tumor model. An antileukemic activity of the studied original conjugate was found. The criterion “increase of life span” (ILS%) reached maximally 136,6% for the conjugate. The studied conjugate of biopolymer dextran with epirubicin showed lower toxicity but also lower antileukemic activity in comparison with free epirubicin. The further experiments in this field are in progress, aiming to design better conjugates, with potential clinical use. © 2004 Taylor and Francis Group, LLC.
  • No Thumbnail Available
    Item
    Antileukemic effect of epirubicin conjugated with chitosan against mouse p388 ascitic leukemia
    (2003-01-01) Todorova N.; Maneva K.; Ilarionova M.; Dudov A.; Todorov D.
    The antileukemic activity of the original conjugate of anthracycline antitumor antibiotic epirubicin, covalently bond to the biopolymer chitosan was studied. The ascitic form of lymphocytic leukemia P388 (transplantation dose 1 × 106 tumor cells/mouse), in hybrid mice BDF1 was used as leukemic model. A strong antileukemic activity of the studied conjugate was found, with a clear “dose-effect” correlation. The criterion “increase of life span”(ILS%) reached maximally 553.4% for the conjugate, in comparison with maximally 170.8% for the free epirubicin. The conjugate showed several advantages over the free antitumor antibiotic epirubicin: lower toxicity, stronger antileukemic activity and higher therapeutic index. © 2003 Taylor and Francis Group, LLC.